Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma

To explore the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with targeted therapy for primary hepatocellular carcinoma (PHC). This was a retrospective study. Retrospective selection of 150 PHC patients admitted to the Renmin Hospital, Hubei University of Medicine J...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pakistan journal of medical sciences 2024-09, Vol.40 (8), p.1663
Hauptverfasser: Wang, Xiao, Zhang, Dan, Li, Kang, Guo, Peng, Lei, Zhi-Xiong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 8
container_start_page 1663
container_title Pakistan journal of medical sciences
container_volume 40
creator Wang, Xiao
Zhang, Dan
Li, Kang
Guo, Peng
Lei, Zhi-Xiong
description To explore the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with targeted therapy for primary hepatocellular carcinoma (PHC). This was a retrospective study. Retrospective selection of 150 PHC patients admitted to the Renmin Hospital, Hubei University of Medicine January 2019 and June 2021 were included. The patients were divided into the control group and the experimental group according to their treatment regimens. The control group received TACE treatment, while the experimental group received TACE combined with targeted therapy. We analyze the relevant data of two groups of patients and evaluate the clinical efficacy and safety of TACE combined with targeted therapy. The tumor remission rate and control rate in the control group were 41.89% and 75.68%, respectively, while those in the experimental group were 77.63% and 90.79%, with statistically significant differences (p
doi_str_mv 10.12669/pjms.40.8.8982
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_3106039162</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A807377868</galeid><sourcerecordid>A807377868</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-1bfe5301d684527e9166800662514787d1fa9315d7f4be012637f709f3ab207e3</originalsourceid><addsrcrecordid>eNptksFrFDEUxgdRbK2evUlAEC8zTSYzSeZYlqqFggdX6C1kMi-dLDPJmmSQ9eo_bqbdqhXJ4SXh9z7e-_iK4jXBFakZ6873uzlWDa5EJTpRPylOCROk5KS9eXp3r0tcNzcnxYsYdxg3rGnr58UJ7WpB6lacFj83k3VWqwldGpOrPiDlBvRFGUgH5A1KQbmoQoJgM6RHmD3MvZ_sD5Wsd2jj5946GNB3m0a0VeEWUn5tRwhqf0DGB7QPdlbhgEbYq-Q1TNMyqYC0Cto6P6uXxTOjpgivjvWs-Prhcrv5VF5__ni1ubgudUNEKklvoKWYDEzkLTh0hDGBMWN1Sxou-ECM6ihpB26aHnD2h3LDcWeo6mvMgZ4V7-9198F_WyAmOdu4jqMc-CVKSjDDNMvWGX37D7rzS3B5upXCHcac8T_UrZpAWmd8dkuvovJCYE45F0xkqvoPlc8As9XegbH5_1HDu78aRlBTGqOfltXv-Bg8vwd18DEGMPJotSRY3uVDrvmQDZZCrvnIHW-Oey39DMNv_iEQ9Be2ybW_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3100900767</pqid></control><display><type>article</type><title>Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Wang, Xiao ; Zhang, Dan ; Li, Kang ; Guo, Peng ; Lei, Zhi-Xiong</creator><creatorcontrib>Wang, Xiao ; Zhang, Dan ; Li, Kang ; Guo, Peng ; Lei, Zhi-Xiong</creatorcontrib><description>To explore the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with targeted therapy for primary hepatocellular carcinoma (PHC). This was a retrospective study. Retrospective selection of 150 PHC patients admitted to the Renmin Hospital, Hubei University of Medicine January 2019 and June 2021 were included. The patients were divided into the control group and the experimental group according to their treatment regimens. The control group received TACE treatment, while the experimental group received TACE combined with targeted therapy. We analyze the relevant data of two groups of patients and evaluate the clinical efficacy and safety of TACE combined with targeted therapy. The tumor remission rate and control rate in the control group were 41.89% and 75.68%, respectively, while those in the experimental group were 77.63% and 90.79%, with statistically significant differences (p&lt;0.05). The 1-year and 3-year recurrence rates in the control group were 52.71% and 98.65%, respectively, while those in the experimental group were 39.47% and 61.84%, with statistically significant differences (p&lt;0.05). After treatment, the AFP, VEGF, ALT, and AST in the experimental group were significantly reduced compared to the control group (p&lt;0.05). During the treatment period, the incidence and severity of nausea, vomiting, and fever in the experimental group were significantly lower than those in the control group (p&lt;0.05). The clinical efficacy of TACE combined with targeted therapy for PHC is superior to that of TACE alone, with improved disease control rate, improved long-term survival rate, and good safety.</description><identifier>ISSN: 1682-024X</identifier><identifier>EISSN: 1681-715X</identifier><identifier>DOI: 10.12669/pjms.40.8.8982</identifier><identifier>PMID: 39281258</identifier><language>eng</language><publisher>Pakistan: Knowledge Bylanes</publisher><subject>Cholangiocarcinoma ; Diarrhea ; Fever ; Health aspects ; Hepatoma ; Hospitals ; Liver ; Liver cancer ; Medical colleges ; Medical prognosis ; Mortality ; Nausea ; Tumors ; Vascular endothelial growth factor</subject><ispartof>Pakistan journal of medical sciences, 2024-09, Vol.40 (8), p.1663</ispartof><rights>Copyright: © Pakistan Journal of Medical Sciences.</rights><rights>COPYRIGHT 2024 Knowledge Bylanes</rights><rights>(c)2024 Pakistan Journal of Medical Sciences</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39281258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Xiao</creatorcontrib><creatorcontrib>Zhang, Dan</creatorcontrib><creatorcontrib>Li, Kang</creatorcontrib><creatorcontrib>Guo, Peng</creatorcontrib><creatorcontrib>Lei, Zhi-Xiong</creatorcontrib><title>Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma</title><title>Pakistan journal of medical sciences</title><addtitle>Pak J Med Sci</addtitle><description>To explore the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with targeted therapy for primary hepatocellular carcinoma (PHC). This was a retrospective study. Retrospective selection of 150 PHC patients admitted to the Renmin Hospital, Hubei University of Medicine January 2019 and June 2021 were included. The patients were divided into the control group and the experimental group according to their treatment regimens. The control group received TACE treatment, while the experimental group received TACE combined with targeted therapy. We analyze the relevant data of two groups of patients and evaluate the clinical efficacy and safety of TACE combined with targeted therapy. The tumor remission rate and control rate in the control group were 41.89% and 75.68%, respectively, while those in the experimental group were 77.63% and 90.79%, with statistically significant differences (p&lt;0.05). The 1-year and 3-year recurrence rates in the control group were 52.71% and 98.65%, respectively, while those in the experimental group were 39.47% and 61.84%, with statistically significant differences (p&lt;0.05). After treatment, the AFP, VEGF, ALT, and AST in the experimental group were significantly reduced compared to the control group (p&lt;0.05). During the treatment period, the incidence and severity of nausea, vomiting, and fever in the experimental group were significantly lower than those in the control group (p&lt;0.05). The clinical efficacy of TACE combined with targeted therapy for PHC is superior to that of TACE alone, with improved disease control rate, improved long-term survival rate, and good safety.</description><subject>Cholangiocarcinoma</subject><subject>Diarrhea</subject><subject>Fever</subject><subject>Health aspects</subject><subject>Hepatoma</subject><subject>Hospitals</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Medical colleges</subject><subject>Medical prognosis</subject><subject>Mortality</subject><subject>Nausea</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><issn>1682-024X</issn><issn>1681-715X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptksFrFDEUxgdRbK2evUlAEC8zTSYzSeZYlqqFggdX6C1kMi-dLDPJmmSQ9eo_bqbdqhXJ4SXh9z7e-_iK4jXBFakZ6873uzlWDa5EJTpRPylOCROk5KS9eXp3r0tcNzcnxYsYdxg3rGnr58UJ7WpB6lacFj83k3VWqwldGpOrPiDlBvRFGUgH5A1KQbmoQoJgM6RHmD3MvZ_sD5Wsd2jj5946GNB3m0a0VeEWUn5tRwhqf0DGB7QPdlbhgEbYq-Q1TNMyqYC0Cto6P6uXxTOjpgivjvWs-Prhcrv5VF5__ni1ubgudUNEKklvoKWYDEzkLTh0hDGBMWN1Sxou-ECM6ihpB26aHnD2h3LDcWeo6mvMgZ4V7-9198F_WyAmOdu4jqMc-CVKSjDDNMvWGX37D7rzS3B5upXCHcac8T_UrZpAWmd8dkuvovJCYE45F0xkqvoPlc8As9XegbH5_1HDu78aRlBTGqOfltXv-Bg8vwd18DEGMPJotSRY3uVDrvmQDZZCrvnIHW-Oey39DMNv_iEQ9Be2ybW_</recordid><startdate>20240930</startdate><enddate>20240930</enddate><creator>Wang, Xiao</creator><creator>Zhang, Dan</creator><creator>Li, Kang</creator><creator>Guo, Peng</creator><creator>Lei, Zhi-Xiong</creator><general>Knowledge Bylanes</general><general>AsiaNet Pakistan (Pvt) Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20240930</creationdate><title>Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma</title><author>Wang, Xiao ; Zhang, Dan ; Li, Kang ; Guo, Peng ; Lei, Zhi-Xiong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-1bfe5301d684527e9166800662514787d1fa9315d7f4be012637f709f3ab207e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cholangiocarcinoma</topic><topic>Diarrhea</topic><topic>Fever</topic><topic>Health aspects</topic><topic>Hepatoma</topic><topic>Hospitals</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Medical colleges</topic><topic>Medical prognosis</topic><topic>Mortality</topic><topic>Nausea</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Xiao</creatorcontrib><creatorcontrib>Zhang, Dan</creatorcontrib><creatorcontrib>Li, Kang</creatorcontrib><creatorcontrib>Guo, Peng</creatorcontrib><creatorcontrib>Lei, Zhi-Xiong</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pakistan journal of medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Xiao</au><au>Zhang, Dan</au><au>Li, Kang</au><au>Guo, Peng</au><au>Lei, Zhi-Xiong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma</atitle><jtitle>Pakistan journal of medical sciences</jtitle><addtitle>Pak J Med Sci</addtitle><date>2024-09-30</date><risdate>2024</risdate><volume>40</volume><issue>8</issue><spage>1663</spage><pages>1663-</pages><issn>1682-024X</issn><eissn>1681-715X</eissn><abstract>To explore the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with targeted therapy for primary hepatocellular carcinoma (PHC). This was a retrospective study. Retrospective selection of 150 PHC patients admitted to the Renmin Hospital, Hubei University of Medicine January 2019 and June 2021 were included. The patients were divided into the control group and the experimental group according to their treatment regimens. The control group received TACE treatment, while the experimental group received TACE combined with targeted therapy. We analyze the relevant data of two groups of patients and evaluate the clinical efficacy and safety of TACE combined with targeted therapy. The tumor remission rate and control rate in the control group were 41.89% and 75.68%, respectively, while those in the experimental group were 77.63% and 90.79%, with statistically significant differences (p&lt;0.05). The 1-year and 3-year recurrence rates in the control group were 52.71% and 98.65%, respectively, while those in the experimental group were 39.47% and 61.84%, with statistically significant differences (p&lt;0.05). After treatment, the AFP, VEGF, ALT, and AST in the experimental group were significantly reduced compared to the control group (p&lt;0.05). During the treatment period, the incidence and severity of nausea, vomiting, and fever in the experimental group were significantly lower than those in the control group (p&lt;0.05). The clinical efficacy of TACE combined with targeted therapy for PHC is superior to that of TACE alone, with improved disease control rate, improved long-term survival rate, and good safety.</abstract><cop>Pakistan</cop><pub>Knowledge Bylanes</pub><pmid>39281258</pmid><doi>10.12669/pjms.40.8.8982</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1682-024X
ispartof Pakistan journal of medical sciences, 2024-09, Vol.40 (8), p.1663
issn 1682-024X
1681-715X
language eng
recordid cdi_proquest_miscellaneous_3106039162
source DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access
subjects Cholangiocarcinoma
Diarrhea
Fever
Health aspects
Hepatoma
Hospitals
Liver
Liver cancer
Medical colleges
Medical prognosis
Mortality
Nausea
Tumors
Vascular endothelial growth factor
title Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T13%3A24%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Efficacy%20and%20Safety%20of%20transarterial%20chemoembolization%20Combined%20with%20Targeted%20Therapy%20for%20primary%20hepatocellular%20carcinoma&rft.jtitle=Pakistan%20journal%20of%20medical%20sciences&rft.au=Wang,%20Xiao&rft.date=2024-09-30&rft.volume=40&rft.issue=8&rft.spage=1663&rft.pages=1663-&rft.issn=1682-024X&rft.eissn=1681-715X&rft_id=info:doi/10.12669/pjms.40.8.8982&rft_dat=%3Cgale_proqu%3EA807377868%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3100900767&rft_id=info:pmid/39281258&rft_galeid=A807377868&rfr_iscdi=true